Tags

Type your tag names separated by a space and hit enter

The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial.
Eur J Health Econ. 2005 Dec; 6(4):354-6, 358-62.EJ

Abstract

The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin. This study evaluated the long-term cost-effectiveness of 12-month vs. 28-day therapy with clopidogrel in Sweden. A Markov model was developed which assumed a hypothetical cohort of patients in a post-PCI state to have certain risks of suffering one of the endpoints of the CREDO trial: stroke, myocardial infarction, or death. The model predicted a mean survival of 12.098 years in the 12-month arm vs. 12.026 in the 28-day arm, an incremental gain of 0.072 life-years. The gain in survival came at a predicted incremental cost of Euro 217, resulting in an incremental cost-effectiveness ratio of Euro 3,022. Thus the predicted cost-effectiveness ratio of long-term treatment with clopidogrel in patients undergoing PCI is well below the threshold values currently considered cost-effective.

Authors+Show Affiliations

Stockholm Health Economics, Stockholm, Sweden. anna.r@healtheconomics.seNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16267654

Citation

Ringborg, Anna, et al. "The Cost-effectiveness of Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: a Swedish Analysis of the CREDO Trial." The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, vol. 6, no. 4, 2005, pp. 354-6, 358-62.
Ringborg A, Lindgren P, Jönsson B. The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. Eur J Health Econ. 2005;6(4):354-6, 358-62.
Ringborg, A., Lindgren, P., & Jönsson, B. (2005). The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care, 6(4), 354-6, 358-62.
Ringborg A, Lindgren P, Jönsson B. The Cost-effectiveness of Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention: a Swedish Analysis of the CREDO Trial. Eur J Health Econ. 2005;6(4):354-6, 358-62. PubMed PMID: 16267654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention: a Swedish analysis of the CREDO trial. AU - Ringborg,Anna, AU - Lindgren,Peter, AU - Jönsson,Bengt, PY - 2005/11/4/pubmed PY - 2006/3/1/medline PY - 2005/11/4/entrez SP - 354-6, 358-62 JF - The European journal of health economics : HEPAC : health economics in prevention and care JO - Eur J Health Econ VL - 6 IS - 4 N2 - The CREDO trial demonstrated the clinical efficacy of 12-month antiplatelet therapy with clopidogrel compared to standard 28-day treatment with a 27% relative reduction in the combined risk of death, myocardial infarction, or stroke in patients undergoing percutaneous coronary intervention (PCI) and being treated with aspirin. This study evaluated the long-term cost-effectiveness of 12-month vs. 28-day therapy with clopidogrel in Sweden. A Markov model was developed which assumed a hypothetical cohort of patients in a post-PCI state to have certain risks of suffering one of the endpoints of the CREDO trial: stroke, myocardial infarction, or death. The model predicted a mean survival of 12.098 years in the 12-month arm vs. 12.026 in the 28-day arm, an incremental gain of 0.072 life-years. The gain in survival came at a predicted incremental cost of Euro 217, resulting in an incremental cost-effectiveness ratio of Euro 3,022. Thus the predicted cost-effectiveness ratio of long-term treatment with clopidogrel in patients undergoing PCI is well below the threshold values currently considered cost-effective. SN - 1618-7598 UR - https://www.unboundmedicine.com/medline/citation/16267654/The_cost_effectiveness_of_dual_oral_antiplatelet_therapy_following_percutaneous_coronary_intervention:_a_Swedish_analysis_of_the_CREDO_trial_ L2 - https://dx.doi.org/10.1007/s10198-005-0323-0 DB - PRIME DP - Unbound Medicine ER -